Download the application note now
Horizon’s 2D OncoSignature™ screening service enables the rapid screening of single agents or drug combinations across a diverse panel of 300 cancer cell lines.
Here we describe the development of a parallel 3D OncoSignature service that enables screening across a panel of 200 cell lines in a spheroid format. We also demonstrate the use of patient-derived organoids as a powerful secondary screening tool to validate the findings of a 2D and spheroid-based 3D screens in a more complex 3D model system.
High throughput cell panel screens are a key drug development tool for identifying sensitive tumor types and genomic features governing response. Two-dimensional (2D) monolayer assay formats are the traditional mainstay for these screens, which have facilitated the development of many successful drugs. However, it is increasingly recognized that they do not accurately model key aspects of the three-dimensional (3D) tumor microenvironment (TME). Therefore, the adoption of high throughput screening approaches using 3D assays to complement 2D approaches could substantially improve prediction of clinical outcomes and reduce the high failure rate of cancer drugs in clinical trials.
Learn more by downloading the full application note